Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPC3 CAR-T-AFP-CD3
- Development stage
- Preclinical
- Lead developer
- OriCell Therapeutics
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GPC3 CAR-T-AFP-CD3 is an investigational dual-targeting chimeric antigen receptor (CAR)-T cell therapy designed for the treatment of hepatocellular carcinoma (HCC). Developed by OriCell Therapeutics in collaboration with the South China University of Technology and Guangdong Medical University, this therapy utilizes T cells engineered to express a CAR targeting the cell-surface tumor antigen Glypican-3 (GPC3). Furthermore, these cells are modified to secrete a bispecific T-cell engager (BiTE) that targets an HLA-A*02:01-restricted epitope of the intracellular antigen Alpha-fetoprotein (AFP) presented on the tumor surface, while simultaneously engaging bystander T cells via the CD3 receptor. This dual-mechanism approach is intended to enhance anti-tumor activity, improve CAR-T cell persistence, and overcome the challenges of antigen heterogeneity and low expression levels often encountered in liver cancer treatment.
- Other names
- Dual-targeting GPC3 CAR-T cells secreting AFP-BiTEGPC3-targeting CAR-T cells secreting AFP-CD3 BiTEGPC-3-targeting CAR-T cells secreting AFP-CD3 BiTEGPC 3-targeting CAR-T cells secreting AFP-CD3 BiTE
02
Targets
AFP (Alpha-fetoprotein)GPC3 (Glypican-3)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on GPC3 CAR-T-AFP-CD3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPC3 CAR-T-AFP-CD3.